29.38

4.36% 1.285

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $29.38, with a volume of 919.73K. It is up +4.36% in the last 24 hours and down -6.13% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$28.09

Open:

$28.72

24h Volume:

919.73K

Relative Volume:

1.75

Market Cap:

$2.04B

Revenue:

Net Income/Loss:

$-179.27M

P/E Ratio:

-11.47

EPS:

-2.56

Net Cash Flow:

$-155.88M

1W Performance:

-11.27%

1M Performance:

-6.13%

6M Performance:

+47.16%

1Y Performance:

+87.68%

1-Day Range:

$28.44

$29.58

1-Week Range:

$27.05

$34.54

52-Week Range:

$15.32

$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO	29.36	2.04B	0	-179.27M	-155.88M	-2.56
VRTX	467.21	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	761.02	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	564.61	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.30	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.69	24.08B	3.30B	-501.07M	1.03B	11.54

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

08:32 AM

HC Wainwright Reaffirms "Buy" Rating for Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

08:32 AM

07:34 AM

Citigroup Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

07:34 AM

Nov 15, 2024

Akero Therapeutics (NASDAQ:AKRO) Shares Down 6.4%What's Next? - MarketBeat

Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Boosted by Simplify Asset Management Inc. - MarketBeat

Nov 15, 2024

Akero Therapeutics to Showcase New Analyses of Phase 2b - GlobeNewswire

Nov 15, 2024

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 - Marketscreener.com

Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Decline in Short Interest - MarketBeat

Nov 15, 2024

Janus Henderson Group PLC's Strategic Acquisition of Akero Thera - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

RTW INVESTMENTS, LP Expands Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024

Akero Therapeutics to Present at Jefferies London Healthcare Conference | AKRO Stock News - StockTitan

Nov 13, 2024

ALKEON CAPITAL MANAGEMENT LLC Reduces Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 13, 2024

FY2028 EPS Forecast for Akero Therapeutics Raised by Analyst - MarketBeat

Nov 13, 2024

Akero Therapeutics (NASDAQ:AKRO) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 13, 2024

Nov 12, 2024

Akero Therapeutics Advances in MASH Treatment Trials - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateAkero Therapeutics, Inc. made significant strides in the third quarter of 2024, announcing the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study of i - Defense World

Nov 11, 2024

Nov 09, 2024

Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Misses Estimates By $0.15 EPS - MarketBeat

Nov 09, 2024

Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock - Investing.com

Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock By Investing.com - Investing.com Australia

Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition of Akero Therapeutics Shares - GuruFocus.com

Nov 08, 2024